Anemia development and cardiovascular risk management in nonanemic stage 3 chronic kidney disease

Renal Failure

Volumn 31, Issue 10, 2009, Pages 869-875

  Portolés, José ^a,b   Castelao, Alberto Martinez ^c   Gorriz, Jose Luis ^d   Tato, Ana Maria ^e   De Alvaro, Fernando ^e  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b REDinREN ^*  (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Anemia; Cardiovascular risk; Chronic kidney disease; Diabetes; Epidemiology

Indexed keywords

HEMOGLOBIN; IRON;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CIGARETTE SMOKING; COMORBIDITY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DYSLIPIDEMIA; FEMALE; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RISK FACTOR; RISK MANAGEMENT;

ADULT; AGED; ANEMIA; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RESEARCH DESIGN; SPAIN; YOUNG ADULT;

EID: 73649090017     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860220903216063     Document Type: Article

References (29)

1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42:1050-1065.
2. García de Vinuesa S. Progression factors for chronic kidney disease. Secondary prevention. Nefrología. 2008;28(Suppl. 3):17-21.
3. Portolés J, Lopez JM, Aljama P, Tato A. CV risk in HD in Spain: Prevalence, management and target results (MAR Study). Nefrología. 2005;24:83-92.
4. Eschbach J, Adamson J. Anaemia of end-stage renal disease (ESDR). Kidney Int. 1985;28:1-5.
5. Eschbach J. The anaemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989;35:134-148. (Pubitemid 19047434)
6. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anaemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2002;162:1401-1408.
7. Locatelli F, Aljama P, Bárány P, et al. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(Suppl. 2):1-47.
8. Eschbach J. Current concepts of anaemia management in chronic renal failure: Impact of NKF-DOQI. Semin Nephrol. 2000;20:320-329.
9. Moreno F, Valderrábano F. Treatment of anaemia with erythropoietin in chronic kidney disease. In: Llach F, Valderrábano F (eds.). Enfermedad renal crónica. Madrid: Norma;1997: 449-474.
10. Kazmi WH, Kausz AT, Kan S, et al. Anemia: An early complication of chronic renal insufficiency. Am J Kidney Dis. 2001;38:803-812.
11. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
12. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245-1251.
13. Fried L, Bernardini J, Piraino B. Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. Am J Kidney Dis. 2001;37:337-342.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
15. American Diabetes Association. Standards of medical care for patients with diabetes mellitus (position statement). Diabetes Care. 2006;29:S4-S42.
16. De Nicola L, Minutolo R, Chiodini P, et al. Target Blood Pressure Levels in Chronic Kidney Disease (TABLE in CKD) Study Group. Global approach to cardiovascular risk in chronic kidney disease: Reality and opportunities for intervention. Kidney Int. 2006;69:538-545.
17. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease. Evaluation, Classification, and Stratification. Available at: http:// www.kidney.org/professionals/KDOQI/ (accessed October 31, 2008).
18. Otero A, Gayoso P, Garcia F, de Francisco AL, on behalf of the EPIRCE Study Group. Epidemiology of chronic renal disease in the Galician population: Results of the pilot Spanish EPIRCE study. Kidney Int Suppl. 2005;99:S16-S19.
19. Portolés J, López-Gómez JM, Aljama P. Anemia management and treatment response in patients on hemodialysis: The Mar Study. J Nephrology. 2006;19:352-360.
20. Coresh J, Astor BC, Greene T, Eknoyan G, Levey A. Prevalence of chronic kidney disease and decreased kidney function in the adult U.S. population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1-12.
21. Portolés J, López-Gómez JM, Aljama P. A prospective study of the role of anaemia as a risk factor in HD patients. Nephrol Dial Transplant. 2007;22:500-507.
22. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in hemodialysis patients of five European countries: Association with morbidity and mortality in DOPPS. Nephrol Dial Transplant. 2004;19:121-132.
23. Portolés J, Gorriz JL, Martinez-Castelao A, et al. One-year mortality and risk factors management in diabetic vs. nondiabetic patients with chronic kidney disease stages 3 and 4: Merena Study. Nephrol Dial Transplant. 2007 21:393.
24. Keith D, Nichols GA, Gullion CM, Betz JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659-663. (Pubitemid 38392981)
25. Llisterri JL, Rodríguez-Roca GC, Alonso FJ, et al. Control of blood pressure in Spanish hypertensive population attended in primary health care. PRESCAP 2006 Study. Med Clin (Barc). 2008;130:681-687.
26. Fontseré N, Bonal J, Torres F, de las Cuevas X, Fort J. Compliance with the 2002 consensus document of the Spanish Society of Nephrology for the control of diabetic nephropathy in Catalonia (ECCODIAB). Nefrologia. 2006:26:679-687.
27. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289:2560-2572.
28. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl. 3):S1-S201.
29. Johnson DW, Craven AM, Isbel NM. Modification of cardiovascular risk in hemodialysis patients: An evidence-based review. Hemodial Int. 2007;11:1-14.